Gaucher Disease and Bone Manifestations

被引：39

作者：

Marcucci, Gemma ^{[1
]}

Zimran, Ari ^{[2
]}

Bembi, Bruno ^{[3
]}

Kanis, John ^{[4
]}

Reginster, Jean-Yves ^{[5
]}

Rizzoli, Rene ^{[6
,7
]}

Cooper, Cyrus ^{[8
,9
]}

Brandi, Maria Luisa ^{[1
]}

机构：

[1] Univ Florence, Dept Surg & Translat Med, Bone Metab Dis Unit, I-50139 Florence, Italy

[2] Hebrew Univ Jerusalem, Hadassah Med Sch, Shaare Zedek Med Ctr, Gaucher Clin, IL-91010 Jerusalem, Israel

[3] Univ Hosp Santa Maria Misericordia, Reg Coordinat Ctr Rare Dis, Udine, Italy

[4] Univ Sheffield, Sch Med, Ctr Metab Bone Dis, Sheffield, S Yorkshire, England

[5] Univ Liege, Dept Publ Hlth & Hlth Econ, Liege, Belgium

[6] Univ Hosp Geneva, Serv Bone Dis, Geneva, Switzerland

[7] Fac Med, Geneva, Switzerland

[8] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England

[9] Univ Oxford, NIHR Musculoskeletal Biomed Res Unit, Oxford, England

来源：

CALCIFIED TISSUE INTERNATIONAL | 2014年 / 95卷 / 06期

关键词：

Gaucher disease; Bone; Biomarkers; Enzyme replacement therapy; Substrate reduction therapy; Osteonecrosis; ENZYME REPLACEMENT THERAPY; LYSOSOMAL STORAGE DISEASES; VELAGLUCERASE ALPHA; SKELETAL MANIFESTATIONS; MARROW RESPONSES; MINERAL DENSITY; TYPE-1; GLUCOCEREBROSIDASE; IMIGLUCERASE; MIGLUSTAT;

D O I：

10.1007/s00223-014-9923-y

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Gaucher disease is a relatively rare metabolic disease caused by the inherited deficiency of the lysosomal enzyme glucocerebrosidase. Gaucher disease affects multiple organs, among which is the skeleton. Bone involvement occurs frequently in Gaucher disease, and is one of its most debilitating features, reducing the quality of life of patients. Bone status is an important consideration for treatment to ameliorate symptoms and reduce the risk of irreversible complications. We have conducted a systematic review of all the various aspects of Gaucher disease, focusing on different skeletal manifestations, pathophysiology of bone alterations, clinical symptoms, and current diagnostic and therapeutic approaches.

引用

收藏

页码：477 / 494

页数：18

相关论文

共 107 条

[41] Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project [J].

Giraldo, Pilar ;

Alfonso, Pilar ;

Atutxa, Koldo ;

Fernandez-Galan, Maria A. ;

Barez, Abelardo ;

Franco, Rafael ;

Alonso, Dora ;

Martin, Alejandro ;

Latre, Paz ;

Pocovi, Miguel .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (12) :1771-1775

[42] Therapeutic approaches to bone pathology in Gaucher disease: Past, present and future [J].

Goker-Alpan, Ozlem .

MOLECULAR GENETICS AND METABOLISM, 2011, 104 (04) :438-447

[43] ENZYME THERAPY IN TYPE-1 GAUCHER DISEASE - COMPARATIVE EFFICACY OF MANNOSE-TERMINATED GLUCOCEREBROSIDASE FROM NATURAL AND RECOMBINANT SOURCES [J].

GRABOWSKI, GA ;

BARTON, NW ;

PASTORES, G ;

DAMBROSIA, JM ;

BANERJEE, TK ;

MCKEE, MA ;

PARKER, C ;

SCHIFFMANN, R ;

HILL, SC ;

BRADY, RO .

ANNALS OF INTERNAL MEDICINE, 1995, 122 (01) :33-39

[44] Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1 [J].

Grabowski, Gregory A. ;

Kacena, Katherine ;

Cole, J. Alexander ;

Hollak, Carla E. M. ;

Zhang, Lin ;

Yee, John ;

Mistry, Pramod K. ;

Zimran, Ari ;

Charrow, Joel ;

vom Dahl, Stephan .

GENETICS IN MEDICINE, 2009, 11 (02) :92-100

[45] Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease [J].

Hollak, C ;

Maas, M ;

Akkerman, E ;

den Heeten, A ;

Aerts, H .

BLOOD CELLS MOLECULES AND DISEASES, 2001, 27 (06) :1005-1012

[46] Miglustat (Zavesca®) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme [J].

Hollak, Carla E. M. ;

Hughes, Derralynn ;

van Schaik, Ivo N. ;

Schwierin, Barbara ;

Bembi, Bruno .

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 (09) :770-777

[47] Gaucher disease:: Mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA) [J].

Hruska, Kathleen S. ;

LaMarca, Mary E. ;

Scott, C. Ronald ;

Sidransky, Ellen .

HUMAN MUTATION, 2008, 29 (05) :567-583

[48] Glucocerebroside: an evolutionary advantage for patients with Gaucher disease and a new immunomodulatory agent [J].

Ilan, Yaron ;

Elstein, Deborah ;

Zimran, Ari .

IMMUNOLOGY AND CELL BIOLOGY, 2009, 87 (07) :514-524

[49] Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat [J].

Kamath, Ravi S. ;

Lukina, Elena ;

Watman, Nora ;

Dragosky, Marta ;

Pastores, Gregory M. ;

Avila Arreguin, Elsa ;

Rosenbaum, Hanna ;

Zimran, Ari ;

Aguzzi, Rasha ;

Puga, Ana Cristina ;

Norfleet, Andrea M. ;

Peterschmitt, M. Judith ;

Rosenthal, Daniel I. .

SKELETAL RADIOLOGY, 2014, 43 (10) :1353-1360

[50] The 1226G (N370S) Gaucher mutation among patients with Legg-Calve-Perthes disease [J].

Kenet, G ;

Hayek, S ;

Mor, M ;

Lubetsky, A ;

Miller, L ;

Rosenberg, N ;

Mosheiff, D ;

Itzchaki, M ;

Elstein, D ;

Wientroub, S ;

Zimran, A .

BLOOD CELLS MOLECULES AND DISEASES, 2003, 31 (01) :72-74

← 1 2 3 4 5 6 7 8 9 10 →